MedTrace Logo

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients

NCT00863980 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2015-09-03

No results posted yet for this study

Summary

This study is aimed to investigate whether treatment with Telmisartan is more effective than Candesartan in reducing the ischemic cardiovascular events in high-risk patients with cardiovascular disease.

Conditions

  • Acute Myocardial Infarction
  • Angina Pectoris
  • Myocardial Ischemia
  • Acute Coronary Syndrome
  • Hypertension

Interventions

DRUG

Micardis (Telmisartan)

40-80 mg/day oral administration

DRUG

Blopress (Candesartan)

8-12 mg/day oral administration

Sponsors & Collaborators

  • Kyoto Prefectural University of Medicine

    lead OTHER

Principal Investigators

  • Hiroaki Matsubara, MD, PhD · Kyoto Prefectural University of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863980 on ClinicalTrials.gov